Fig. 6.

Loss of Mfn partially impairs Parkin translocation to mitochondria. S2R+ cells were cotransfected with plasmids expressing parkin-GFP and mitoDsRed and treated with control RNAi probe or Mfn RNAi probe before being treated with CCCP or paraquat and analyzed for Parkin-GFP accumulation. Control RNAi-treated cells are represented in Fig. 2. (A) Mfn RNAi-treated cells exposed to CCCP, paraquat, or no stress. Two representative images are shown for each treatment to show variability. (Scale bar: 5 μm.) (B) Percentage of cells with green puncta. The chart shows the mean and SEM for counting of at least four independent well fields containing 70–90 cells/field. Significance was determined by one-way ANOVA with Bonferroni correction (*P < 0.05, ***P < 0.001).